JP2024504377A - Ｄｕｘ４の発現を低減するための化合物及び方法 - Google Patents

Ｄｕｘ４の発現を低減するための化合物及び方法 Download PDF

Info

Publication number
JP2024504377A
JP2024504377A JP2023544331A JP2023544331A JP2024504377A JP 2024504377 A JP2024504377 A JP 2024504377A JP 2023544331 A JP2023544331 A JP 2023544331A JP 2023544331 A JP2023544331 A JP 2023544331A JP 2024504377 A JP2024504377 A JP 2024504377A
Authority
JP
Japan
Prior art keywords
modified
certain embodiments
oligomeric
seq
modified oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544331A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022159712A5 (https=
JP2024504377A5 (https=
Inventor
バラス，ルーベン・イー
ジャファー・ネジャド，ペイマン
リゴ，フランク
フレアー，スーザン・エム
ブイ，フィン・ホア
シング，プリヤム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of JP2024504377A publication Critical patent/JP2024504377A/ja
Publication of JPWO2022159712A5 publication Critical patent/JPWO2022159712A5/ja
Publication of JP2024504377A5 publication Critical patent/JP2024504377A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023544331A 2021-01-22 2022-01-21 Ｄｕｘ４の発現を低減するための化合物及び方法 Pending JP2024504377A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163140674P 2021-01-22 2021-01-22
US63/140,674 2021-01-22
US202163217624P 2021-07-01 2021-07-01
US63/217,624 2021-07-01
US202163231559P 2021-08-10 2021-08-10
US63/231,559 2021-08-10
PCT/US2022/013323 WO2022159712A1 (en) 2021-01-22 2022-01-21 Compounds and methods for reducing dux4 expression

Publications (3)

Publication Number Publication Date
JP2024504377A true JP2024504377A (ja) 2024-01-31
JPWO2022159712A5 JPWO2022159712A5 (https=) 2025-01-24
JP2024504377A5 JP2024504377A5 (https=) 2025-01-24

Family

ID=82549881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544331A Pending JP2024504377A (ja) 2021-01-22 2022-01-21 Ｄｕｘ４の発現を低減するための化合物及び方法

Country Status (4)

Country Link
US (1) US20240336915A1 (https=)
EP (1) EP4281084A4 (https=)
JP (1) JP2024504377A (https=)
WO (1) WO2022159712A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
EP4370678A2 (en) * 2021-07-14 2024-05-22 Mirecule, Inc. Oligonucleotides and compositions thereof for neuromuscular disorders
EP4590308A2 (en) * 2022-09-23 2025-07-30 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing mecp2 expression
JP2025532127A (ja) 2022-09-23 2025-09-29 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｍｅｃｐ２発現を低減する化合物及び方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322169A1 (en) * 2011-07-25 2014-10-30 Nationwide Children's Hospital, Inc. Recombinant Virus Products and Methods for Inhibition of Expression of DUX4
WO2017050836A1 (en) * 2015-09-21 2017-03-30 Association Institut De Myologie Antisense oligonucleotides and uses thereof
US20200291398A1 (en) * 2017-09-19 2020-09-17 Children's National Medical Center Gapmers and methods of using the same for the treatment of muscular dystrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120225034A1 (en) * 2010-09-02 2012-09-06 Universite De Mons Agents useful in treating facioscapulohumeral muscular dystrophy
US10538763B2 (en) * 2015-01-16 2020-01-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of DUX4
AU2019218987B2 (en) * 2018-02-12 2025-04-24 Ionis Pharmaceuticals, Inc. Modified compounds and uses thereof
US20220195431A1 (en) * 2019-02-22 2022-06-23 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn3 expression
TW202104595A (zh) * 2019-03-29 2021-02-01 日商田邊三菱製藥股份有限公司 用來調節ｄｕｘ４的表現之化合物、方法及醫藥組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322169A1 (en) * 2011-07-25 2014-10-30 Nationwide Children's Hospital, Inc. Recombinant Virus Products and Methods for Inhibition of Expression of DUX4
WO2017050836A1 (en) * 2015-09-21 2017-03-30 Association Institut De Myologie Antisense oligonucleotides and uses thereof
US20200291398A1 (en) * 2017-09-19 2020-09-17 Children's National Medical Center Gapmers and methods of using the same for the treatment of muscular dystrophy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHISTIAKOV DA. ET AL.: "Strategies to deliver microRNAs as potential therapeutics in the treatment of cardiovascular patholo", DRUG DELIV., vol. vol.19(8), JPN6025050835, 2012, pages 392 - 405, ISSN: 0005751666 *
CHORN G. ET AL.: "Single-stranded microRNA mimics", RNA, vol. vol.18(10), JPN6025050834, 2012, pages 1796 - 1804, ISSN: 0005751665 *
LIM KRQ. ET AL.: "Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscul", PROC NATL ACAD SCI U S A, vol. vol.117(28), JPN6025050833, 14 June 2020 (2020-06-14), pages 16509 - 16515, ISSN: 0005751664 *

Also Published As

Publication number Publication date
EP4281084A4 (en) 2025-05-21
EP4281084A1 (en) 2023-11-29
WO2022159712A1 (en) 2022-07-28
US20240336915A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP7557469B2 (ja) Ａｐｐの発現を低減するための化合物及び方法
JP7110485B2 (ja) Ｐｎｐｌａ３発現のモジュレーター
JP2024520205A (ja) Ｕｎｃ１３ａの発現を調節するための化合物
JP2024504377A (ja) Ｄｕｘ４の発現を低減するための化合物及び方法
WO2023064707A1 (en) Compounds and methods for reducing tau expression
JP7550165B2 (ja) Ｕｂｅ３ａ－ａｔｓを調節するための化合物及び方法
JP2023536472A (ja) Ａｐｐの発現を低減するための化合物及び方法
JP2024540537A (ja) プログラニュリン発現を調節するための化合物及び方法
JP2024506351A (ja) Ｐｌｎの発現を低減するための化合物及び方法
JP2024523363A (ja) Ｉｆｎａｒ１の発現を低減するための化合物及び方法
JP2024505226A (ja) ハンチンチンを調節するための化合物及び方法
JP2023543215A (ja) Ａｐｏｅの発現を低減するための化合物及び方法
JP2023530072A (ja) Ｐｍｐ２２を調節するための化合物及び方法
JP2026507572A (ja) アルファ－シヌクレイン発現を調節するための化合物および方法
JP2026506010A (ja) Ａｐｐ発現を低減するための化合物及び方法
JP2026506091A (ja) ハンチンチン発現を調節するための対立遺伝子選択的化合物及び方法
EP4590308A2 (en) Compounds and methods for reducing mecp2 expression
JP7799640B2 (ja) Ｐｌｐ１を調節するための化合物及び方法
JP2023544162A (ja) Ｃｈｍｐ７を調節するための化合物
EP4519441A2 (en) Rnai agents for modulating snca
JP2025500438A (ja) Ｐｃｄｈ１９発現を低減するための化合物及び方法
AU2022377400A1 (en) Compounds and methods for reducing psd3 expression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260126